Phio Pharmaceuticals Corp. (PHIO)
| Market Cap | 16.82M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.99M |
| Shares Out | 5.78M |
| EPS (ttm) | -2.74 |
| PE Ratio | n/a |
| Forward PE | 1.04 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $2.91 |
| Previous Close | $2.99 |
| Change ($) | -0.08 |
| Change (%) | -2.68% |
| Day's Open | 3.03 |
| Day's Range | 2.87 - 3.09 |
| Day's Volume | 223,816 |
| 52-Week Range | 1.68 - 9.77 |
MARLBOROUGH, Mass., Jan. 4, 2021 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its ...
MARLBOROUGH, Mass., Nov. 19, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...
MARLBOROUGH, Mass., Nov. 10, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...
MARLBOROUGH, Mass., Nov. 9, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its ...
MARLBOROUGH, Mass., Oct. 26, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its...
MARLBOROUGH, Mass., Sept. 9, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., Aug. 12, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) shares more than doubled on Friday after the firm announced positive data from its cancer study at the American Society of Clinical Oncology (ASCO) 20...
MARLBOROUGH, Mass., May 14, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its ...
About PHIO
Phio Pharmaceuticals, a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune ... [Read more...]
| Industry Biotechnology | |
| CEO Gerrit Dispersyn | Employees 11 |
| Stock Exchange NASDAQ | Ticker Symbol PHIO |
Financial Performance
In 2019, PHIO's revenue was $21,000, a decrease of -84.78% compared to the previous year's $138,000. Losses were -$8.91 million, 21.0% more than in 2018.
Analyst Forecasts
According to one analyst, the rating for PHIO stock is "Buy" and the 12-month stock price forecast is 4.00.